SelvitaWAR:SLV +3.27%81 ROE % is -6.82% as of Mar. 2026. GuruFocus rates WAR:SLV with a GF Score™ of 81/100 and a GF Value™ of zł58.46 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Selvita ranks better than 50.25% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Selvita's annualized net income for the quarter that ended in Mar. 2026 was zł-21.8 Mil. Selvita's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was zł319.4 Mil. Therefore, Selvita's annualized ROE % for the quarter that ended in Mar. 2026 was -6.82%.
The historical rank and industry rank for Selvita's ROE % or its related term are showing as below:
WAR:SLV'
s ROE % Range Over the Past 10 Years
Min: -1.88 Med: 8.66 Max: 25.64
Current: -1.15
During the past 11 years, Selvita's highest ROE % was 25.64%. The lowest was -1.88%. And the median was 8.66%.
WAR:SLV's ROE % is ranked better than 50.25% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.22
vs WAR:SLV: -1.15
Selvita (WAR:SLV) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Selvita ROE % Related Terms
Selvita ROE % Historical Data
* Premium members only.
The historical data trend for Selvita's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Selvita's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Selvita ROE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Selvita's ROE % distribution charts can be found below:
* The bar in red indicates where Selvita's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Selvita (WAR:SLV) has a ROE % of -6.82% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Selvita and its competitors. According to the industry distribution chart, Selvita ranks #101 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 49.8%.
Is Selvita's ROE % too high?
Selvita's current ROE % is -6.82%. Based on the distribution chart, Selvita ranks #101 out of 203 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Selvita has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Selvita's ROE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Selvita ranks #101 out of 203 companies for ROE %. This puts Selvita in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Diagnostics & Research company?
A good ROE % depends on the Medical Diagnostics & Research industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Selvita and its competitors. Selvita's current ROE % is -6.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Selvita stock overvalued right now?
Based on GuruFocus' analysis, Selvita (WAR:SLV) is currently considered Significantly Undervalued. The stock's GF Value™ is zł58.46, compared to a current price of zł31.60 — trading 45.9% below its estimated fair value. The current ROE % is -6.82%. Selvita's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Selvita (WAR:SLV), the current ROE % is -6.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Selvita (WAR:SLV) Overvalued in 2026?
Based on GuruFocus' analysis, Selvita stock appears to be undervalued.
The current stock price of zł31.60 is trading 45.9% below its estimated GF Value™ of zł58.46.
GuruFocus considers Selvita to be Significantly Undervalued.
Key valuation signals for WAR:SLV:
ROE %: -6.82%
GF Value™: zł58.46 vs. price of zł31.60 (45.9% below fair value)
No single metric tells the full story. See the WAR:SLV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Selvita SA is a Poland based parent company of Selvita Group is one of the largest preclinical contract research organizations in Europe. It also develops bioinformatics solutions supporting innovative projects at preclinical stages. It also provides services provided to external contractors are in the field of chemistry, analytics, regulatory, biochemistry and cell biology and also the integrated research and development projects.
81GF Score
Get the complete analysis for WAR:SLV
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SLV has been successfully added to your 
